Literature DB >> 30562053

Human Rhinovirus Impairs the Innate Immune Response to Bacteria in Alveolar Macrophages in Chronic Obstructive Pulmonary Disease.

Lydia J Finney1, Kylie B R Belchamber1, Peter S Fenwick1, Samuel V Kemp1,2, Michael R Edwards1, Patrick Mallia1, Gavin Donaldson1, Sebastian L Johnston1, Louise E Donnelly1, Jadwiga A Wedzicha1.   

Abstract

Rationale: Human rhinovirus (HRV) is a common cause of chronic obstructive pulmonary disease (COPD) exacerbations. Secondary bacterial infection is associated with more severe symptoms and delayed recovery. Alveolar macrophages clear bacteria from the lung and maintain lung homeostasis through cytokine secretion. These processes are defective in COPD. The effect of HRV on macrophage function is unknown.
Objectives: To investigate the effect of HRV on phagocytosis and cytokine response to bacteria by alveolar macrophages and monocyte-derived macrophages (MDM) in COPD and healthy control subjects.
Methods: Alveolar macrophages were obtained by bronchoscopy and MDM by adherence. Macrophages were exposed to HRV16 (multiplicity of infection 5), polyinosinic:polycytidylic acid (poly I:C) 30 μg/ml, IFN-β 10 μg/ml, IFN-γ 10 μg/ml, or medium control for 24 hours. Phagocytosis of fluorescently labeled Haemophilus influenzae or Streptococcus pneumoniae was assessed by fluorimetry. CXCL8 (IL-8), IL-6, TNF-α (tumor necrosis factor-α), and IL-10 release was measured by ELISA. Measurements and Main
Results: HRV significantly impaired phagocytosis of H. influenzae by 23% in MDM (n = 37; P = 0.004) and 18% in alveolar macrophages (n = 20; P < 0.0001) in COPD. HRV also significantly reduced phagocytosis of S. pneumoniae by 33% in COPD MDM (n = 20; P = 0.0192). There was no effect in healthy control subjects. Phagocytosis of H. influenzae was also impaired by poly I:C but not IFN-β or IFN-γ in COPD MDM. HRV significantly reduced cytokine responses to H. influenzae. The IL-10 response to H. influenzae was significantly impaired by poly I:C, IFN-β, and IFN-γ in COPD cells. Conclusions: HRV impairs phagocytosis of bacteria in COPD, which may lead to an outgrowth of bacteria. HRV also impairs cytokine responses to bacteria via the TLR3/IFN pathway, which may prevent resolution of inflammation leading to prolonged exacerbations in COPD.

Entities:  

Keywords:  COPD; bacteria; macrophages; phagocytosis; rhinovirus

Mesh:

Year:  2019        PMID: 30562053     DOI: 10.1164/rccm.201806-1095OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  17 in total

Review 1.  [Rhinoviruses].

Authors:  A Grünewaldt; C Hügel; G G U Rohde
Journal:  Internist (Berl)       Date:  2019-11       Impact factor: 0.743

2.  Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study.

Authors:  Yoshihiko Raita; Marcos Pérez-Losada; Robert J Freishtat; Andrea Hahn; Eduardo Castro-Nallar; Ignacio Ramos-Tapia; Nathaniel Stearrett; Yury A Bochkov; James E Gern; Jonathan M Mansbach; Zhaozhong Zhu; Carlos A Camargo; Kohei Hasegawa
Journal:  Eur Respir J       Date:  2022-07-13       Impact factor: 33.795

3.  Targeted Retreatment of Incompletely Recovered Chronic Obstructive Pulmonary Disease Exacerbations with Ciprofloxacin. A Double-Blind, Randomized, Placebo-controlled, Multicenter, Phase III Clinical Trial.

Authors:  Andrew I Ritchie; Simon E Brill; Ben H Vlies; Lydia J Finney; James P Allinson; Luana Alves-Moreira; Dexter J Wiseman; Paul P Walker; Emma Baker; Sarah L Elkin; Patrick Mallia; Martin Law; Gavin C Donaldson; Peter M A Calverley; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2020-08-15       Impact factor: 21.405

4.  Arpin is critical for phagocytosis in macrophages and is targeted by human rhinovirus.

Authors:  Jamil Jubrail; Kshanti Africano-Gomez; Floriane Herit; Anna Mularski; Pierre Bourdoncle; Lisa Oberg; Elisabeth Israelsson; Pierre-Regis Burgel; Gaell Mayer; Danen M Cunoosamy; Nisha Kurian; Florence Niedergang
Journal:  EMBO Rep       Date:  2019-11-13       Impact factor: 8.807

5.  Ability of procalcitonin to distinguish between bacterial and nonbacterial infection in severe acute exacerbation of chronic obstructive pulmonary syndrome in the ICU.

Authors:  Cédric Daubin; François Fournel; Fabrice Thiollière; Fabrice Daviaud; Michel Ramakers; Andréa Polito; Bernard Flocard; Xavier Valette; Damien Du Cheyron; Nicolas Terzi; Muriel Fartoukh; Stephane Allouche; Jean-Jacques Parienti
Journal:  Ann Intensive Care       Date:  2021-03-06       Impact factor: 6.925

6.  Human Rhinovirus Inhibits Macrophage Phagocytosis of Bacteria in Chronic Obstructive Pulmonary Disease. More Than a Common Cold.

Authors:  Ian Sabroe; Antonia Ho; David H Dockrell
Journal:  Am J Respir Crit Care Med       Date:  2019-06-15       Impact factor: 21.405

7.  Early respiratory viral infections in infants with cystic fibrosis.

Authors:  Ashley R Deschamp; Joseph E Hatch; James E Slaven; Netsanet Gebregziabher; Gregory Storch; Graham L Hall; Stephen Stick; Sarath Ranganathan; Thomas W Ferkol; Stephanie D Davis
Journal:  J Cyst Fibros       Date:  2019-02-27       Impact factor: 5.482

Review 8.  Respiratory Viral Infections in Exacerbation of Chronic Airway Inflammatory Diseases: Novel Mechanisms and Insights From the Upper Airway Epithelium.

Authors:  Kai Sen Tan; Rachel Liyu Lim; Jing Liu; Hsiao Hui Ong; Vivian Jiayi Tan; Hui Fang Lim; Kian Fan Chung; Ian M Adcock; Vincent T Chow; De Yun Wang
Journal:  Front Cell Dev Biol       Date:  2020-02-25

Review 9.  Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations.

Authors:  Andrew I Ritchie; Jadwiga A Wedzicha
Journal:  Clin Chest Med       Date:  2020-09       Impact factor: 2.878

10.  Characteristics of Hospitalized Rhinovirus-Associated Community-Acquired Pneumonia in Children, Finland, 2003-2014.

Authors:  Maria Hartiala; Elina Lahti; Ville Forsström; Tytti Vuorinen; Olli Ruuskanen; Ville Peltola
Journal:  Front Med (Lausanne)       Date:  2019-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.